In MM, the addition of an anti-PD-L1 mAb to anti-FcRH5/CD3 BsAb therapy significantly increased the efficiency of MM cell killing in vitro and in vivo, restoring T cell activity (188). The gene discussed is FCRL5; the disease is Miyoshi myopathy.